3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
11
Head and Neck Neoplasms
5
Breast Neoplasms
3
Adenocarcinoma of Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Gliosarcoma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Untreated Childhood Anaplastic Astrocytoma
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Salivary Gland Neoplasms
1
Recurrence
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Lymphoid Interstitial Pneumonia
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
Gefitinib
×
Clear all
No trials found.